BioXcel Therapeutics: FDA Accepts IGALMI Application FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts.

BioXcel Therapeutics: FDA Accepts IGALMI Application: FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts. 👈 Read full analysis #BioXcelTherapeutics #IGALMI #FDANews #Pharmaceuticals #DrugApproval